Neumora Therapeutics(NMRA)

搜索文档
CLASS ACTION NOTICE FOR NMRA: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses to Contact the Firm
Prnewswire· 2025-04-01 00:31
DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ("MDD") to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) ...
NMRA IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
GlobeNewswire News Room· 2025-03-29 06:02
文章核心观点 罗森律师事务所提醒购买纽莫拉治疗公司2023年9月首次公开募股普通股的投资者,2025年4月7日是证券集体诉讼首席原告的截止日期,投资者或可获得赔偿 [1][2] 案件详情 - 招股文件包含虚假或误导性陈述,未披露为开展三期项目,公司修改二期试验纳入标准,纳入中重度重度抑郁症患者以显示药物疗效 [5] - 公司还在二期统计分析计划中增加针对中重度重度抑郁症患者的预设分析 [5] - 二期试验数据不足,尤其在患者群体规模和男女患者比例方面,无法准确预测KOASTAL - 1研究结果,真相公开后投资者受损 [5] 后续行动 - 加入纽莫拉集体诉讼可访问指定网址、致电或发邮件了解相关信息 [3][6] - 若想担任首席原告,须在2025年4月7日前向法院提出申请,首席原告代表其他集体成员指导诉讼 [3] 选择罗森律师事务所的原因 - 鼓励投资者选择有成功记录的合格律师,很多发布通知的律所缺乏经验、资源和同行认可,只是中介 [4] - 罗森律师事务所代表全球投资者,专注证券集体诉讼和股东派生诉讼,曾达成针对中国公司的最大证券集体诉讼和解 [4] - 2017年该律所证券集体诉讼和解数量排名第一,自2013年起每年排名前四,为投资者追回数亿美元,2019年为投资者获超4.38亿美元赔偿 [4]
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NMRA
Prnewswire· 2025-03-28 17:45
文章核心观点 Levi & Korsinsky, LLP 就 Neumora Therapeutics, Inc. 证券欺诈提起集体诉讼,为受影响投资者追讨损失 [1][2] 分组1:集体诉讼相关信息 - 诉讼旨在为受证券欺诈影响的 Neumora Therapeutics 投资者追讨损失,代表自 2023 年 9 月 15 日左右起依据发行文件购买或获得公司普通股的投资者 [2] - 投资者可通过链接获取更多信息并与团队成员联系,也可通过邮件或电话联系 Joseph E. Levi, Esq. [2] 分组2:案件详情 - 投诉称被告作出虚假陈述或隐瞒信息,包括为开展三期项目修改二期试验纳入标准、增加预设分析以及二期试验数据不足以准确预测 KOASTAL - 1 研究结果 [3] 分组3:后续安排 - 若在相关时间段内遭受损失,投资者需在 2025 年 4 月 7 日前请求法院指定为首席原告,不担任首席原告也可参与赔偿分配 [4] - 作为集体成员,投资者无需支付任何自付费用或费用即可获得赔偿,参与无成本和义务 [4] 分组4:律所优势 - 过去 20 年,Levi & Korsinsky 团队为受害股东争取数亿美元赔偿,在复杂证券诉讼中经验丰富,有超 70 名员工服务客户 [5] - 连续七年位列 ISS 证券集体诉讼服务机构美国前 50 大证券诉讼律所 [5] 分组5:联系方式 - 律所信息包括地址、邮箱、电话、传真和网址 [6]
April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NMRA
GlobeNewswire News Room· 2025-03-28 00:52
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA
Prnewswire· 2025-03-27 17:45
文章核心观点 格罗斯律师事务所通知Neumora Therapeutics股东参与集体诉讼,指控公司在特定时期发布虚假误导声明或未披露关键信息,鼓励符合条件股东联系律所,申请首席原告截止日期为2025年4月7日 [1][2][3] 分组1:诉讼基本信息 - 律所鼓励在特定时期购买Neumora Therapeutics股票的股东联系,申请首席原告非参与赔偿必要条件 [1] - 集体诉讼代表在2023年9月15日左右开始,依据发行文件购买或获得Neumora普通股的群体 [1] - 申请首席原告截止日期为2025年4月7日,股东注册后将使用投资组合监控软件获取案件进展 [3] 分组2:诉讼指控内容 - 为开展三期项目,公司修改BlackThorn二期试验纳入标准,纳入中重度抑郁症患者以显示旗舰候选药物Navacaprant疗效 [2] - 公司在二期统计分析计划中增加针对中重度抑郁症患者的预设分析 [2] - 二期试验数据不足,尤其在患者群体规模和男女患者比例方面,无法准确预测KOASTAL - 1研究结果 [2] 分组3:律所相关信息 - 格罗斯律师事务所是全国知名集体诉讼律所,使命是保护因欺诈等受损投资者权益 [4] - 律所致力于确保公司负责任经营,为因公司虚假陈述等导致损失的投资者寻求赔偿 [4] 分组4:联系方式 - 律所地址为纽约西38街15号12楼,邮箱为[email protected],电话为(646) 453 - 8903 [5]
NMRA DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Investors of Deadline and Encourages Investors with Losses to Contact the Firm
Prnewswire· 2025-03-27 02:35
RADNOR, Pa., March 26, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or aro ...
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion
GlobeNewswire News Room· 2025-03-26 05:40
LOS ANGELES, March 25, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commencing on or about September 15, 2023. Neumora investors have until April 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-888 ...
NMRA Investors Have Final Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Prnewswire· 2025-03-25 21:34
LOS ANGELES, March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ: NMRA) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the ...
Neumora Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA
Prnewswire· 2025-03-24 17:45
NEW YORK, March 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=137688&from=4CLASS PERIOD: ...
NMRA CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Shareholders of Securities Fraud Class Action Lawsuit
Prnewswire· 2025-03-22 08:06
文章核心观点 Kessler Topaz Meltzer & Check, LLP告知投资者已对Neumora Therapeutics, Inc.提起证券集体诉讼,指控其在招股文件中存在重大虚假或误导性陈述,投资者可在2025年4月7日前申请成为首席原告 [1][2][3] 分组1:诉讼基本信息 - 律所Kessler Topaz Meltzer & Check, LLP代表在Neumora 2023年9月15日左右首次公开募股中购买其普通股的投资者提起证券集体诉讼 [1] - 首席原告申请截止日期为2025年4月7日 [1][3] 分组2:被告涉嫌不当行为 - 招股文件中被告作出重大虚假或误导性陈述,未披露为开展三期项目,Neumora修改二期试验纳入标准,纳入中重度重度抑郁症患者以显示Navacaprant治疗效果 [2] - Neumora在二期统计分析计划中增加针对中重度重度抑郁症患者的预设分析 [2] - 二期试验缺乏足够数据,尤其在患者群体规模和男女患者比例方面,无法准确预测KOASTAL - 1研究结果 [2] 分组3:首席原告流程 - Neumora投资者可在2025年4月7日前通过Kessler Topaz Meltzer & Check, LLP或其他律师申请成为首席原告代表集体诉讼,也可选择不作为保持缺席集体成员身份 [3] - 首席原告通常是财务利益最大且能代表投资者群体的投资者或小群体,其选择律师代表集体诉讼,律师获法院批准后成为首席或集体律师 [3] - 是否担任首席原告不影响投资者分享赔偿的权利 [3] 分组4:律所相关信息 - Kessler Topaz Meltzer & Check, LLP鼓励遭受重大损失的Neumora投资者联系获取更多信息 [4] - 该律所可通过点击链接或拨打(484) 270 - 1453或发邮件[email protected]联系 [2][4][5] - 律所擅长在国内外州和联邦法院提起集体诉讼,为欺诈和企业不当行为受害者追回数十亿美元 [4]